PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsDaunorubicin
Cerubidine, Vyxeos liposomal (previously known as vyxeos)(daunorubicin)
Cerubidine, Daunorubicin, Daunoxome, Vyxeos (daunorubicin) is a small molecule pharmaceutical. Daunorubicin was first approved as Cerubidine on 1982-01-01. It is used to treat myeloid leukemia acute and precursor cell lymphoblastic leukemia-lymphoma in the USA. It has been approved in Europe to treat myeloid leukemia acute.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
hemic and lymphatic diseasesD006425
immune system diseasesD007154
Trade Name
FDA
EMA
Cerubidine, Daunorubicin (discontinued: Cerubidine, Daunorubicin, Daunoxome)
Combinations
Vyxeos
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Daunorubicin citrate
Tradename
Company
Number
Date
Products
DAUNOXOMEGalen PharmaN-050704 DISCN1996-04-08
1 products
Hide discontinued
Daunorubicin hydrochloride
Tradename
Company
Number
Date
Products
DAUNORUBICIN HYDROCHLORIDEHikma PharmaceuticalsN-050731 RX1998-01-30
1 products, RLD, RS
Show 1 discontinued
Cytarabine
+
Daunorubicin
Tradename
Company
Number
Date
Products
VYXEOSCelator PharmaceuticalsN-209401 RX2017-08-03
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
daunorubicin hydrochlorideNew Drug Application2024-02-15
vyxeosNew Drug Application2022-09-27
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
myeloid leukemia acute—D015470C92.0
precursor cell lymphoblastic leukemia-lymphoma—D054198—
leukemia—D007938C95
lymphoma—D008223C85.9
meningeal neoplasmsEFO_0003851D008577C70
Agency Specific
FDA
EMA
Expiration
Code
CYTARABINE / DAUNORUBICIN, VYXEOS, CELATOR PHARMS
2028-03-30ODE-350
2024-08-03ODE-287
2024-03-30NPP
Patent Expiration
Patent
Expires
Flag
FDA Information
Cytarabine / Daunorubicin, Vyxeos, Celator Pharms
100289122032-10-15DPU-3149, U-3150
101661842032-10-15DPU-3149
108354922032-10-15U-3150
80928282029-04-01U-3147
80222792027-09-14DPU-3147
78509902027-01-23DPU-3147
92719312027-01-23DP
85184372026-06-07DP
84318062025-04-22DPU-3147
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01D: Cytotoxic antibiotics and related substances
— L01DB: Anthracyclines and related substances
— L01DB02: Daunorubicin
— L01X: Other antineoplastic agents in atc
— L01XY: Combinations of antineoplastic agents
— L01XY01: Cytarabine and daunorubicin
HCPCS
Code
Description
J9150
Injection, daunorubicin, 10 mg
J9151
Injection, daunorubicin citrate, liposomal formulation, 10 mg
J9153
Injection, liposomal, 1 mg daunorubicin and 2.27 mg cytarabine
Clinical
Clinical Trials
471 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Myeloid leukemia acuteD015470—C92.011132——23
LeukemiaD007938—C959101——19
Myeloid leukemiaD007951—C92982——17
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Myelodysplastic syndromesD009190—D4643———7
NeoplasmsD009369—C8024———5
Precursor cell lymphoblastic leukemia-lymphomaD054198——23———5
PreleukemiaD011289——21———3
Eyelid neoplasmsD005142EFO_1000934——3———3
Neoplasm metastasisD009362EFO_0009708——1——12
Lymphoid leukemiaD007945—C91—2———2
Non-hodgkin lymphomaD008228—C85.911———2
LymphomaD008223—C85.911———2
Myeloproliferative disordersD009196—D47.111———1
Show 9 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
SyndromeD013577——2————2
Hematologic neoplasmsD019337——2————2
Hodgkin diseaseD006689—C811————1
Large b-cell lymphoma diffuseD016403—C83.31————1
Large-cell lymphoma anaplasticD017728—C84.61————1
Burkitt lymphomaD002051—C83.71————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameDaunorubicin
INNdaunorubicin
Description
Daunorubicin is a natural product found in Actinomadura roseola. It has a role as an antineoplastic agent and a bacterial metabolite. It is an anthracycline, a member of tetracenequinones, a member of p-quinones and an aminoglycoside antibiotic. It is a conjugate base of a daunorubicin(1+). It derives from a hydride of a tetracene.
Classification
Small molecule
Drug classantineoplastic antibiotics (daunorubicin type)
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(C)=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1
Identifiers
PDB—
CAS-ID20830-81-3
RxCUI—
ChEMBL IDCHEMBL178
ChEBI ID41977
PubChem CID30323
DrugBankDB00694
UNII IDZS7284E0ZP (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Vyxeos – Jazz Pharmaceuticals
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 21,706 documents
View more details
Safety
Black-box Warning
Black-box warning for: Vyxeos
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
14,436 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use